UNASYN Drug Patent Profile

Which patents cover Unasyn, and when can generic versions of Unasyn launch?

Unasyn is a drug marketed by Pfizer and is included in two NDAs.

The generic ingredient in UNASYN is ampicillin sodium; sulbactam sodium. There are seventy drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the ampicillin sodium; sulbactam sodium profile page.

Summary for UNASYN

US Patents:	0
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Clinical Trials:	8
Drug Prices:	Drug price information for UNASYN
What excipients (inactive ingredients) are in UNASYN?	UNASYN excipients list
DailyMed Link:	UNASYN at DailyMed

See drug prices for UNASYN

Recent Clinical Trials for UNASYN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Pisa University Hospital	Phase 4
Sheba Medical Center	Phase 4
Monaldi Hospital	Phase 4

See all UNASYN clinical trials

Pharmacology for UNASYN

Drug Class	Penicillin-class Antibacterial beta Lactamase Inhibitor
Mechanism of Action	beta Lactamase Inhibitors

US Patents and Regulatory Information for UNASYN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	UNASYN	ampicillin sodium; sulbactam sodium	INJECTABLE;INJECTION	062901-002	Feb 27, 1992		DISCN	No	No
Pfizer	UNASYN	ampicillin sodium; sulbactam sodium	INJECTABLE;INJECTION	050608-001	Dec 31, 1986	AP	RX	Yes	Yes
Pfizer	UNASYN	ampicillin sodium; sulbactam sodium	INJECTABLE;INJECTION	062901-001	Nov 23, 1988		DISCN	No	No
Pfizer	UNASYN	ampicillin sodium; sulbactam sodium	INJECTABLE;INJECTION	050608-002	Dec 31, 1986	AP	RX	Yes	Yes
Pfizer	UNASYN	ampicillin sodium; sulbactam sodium	INJECTABLE;INJECTION	050608-003	Dec 31, 1986		DISCN	No	No
Pfizer	UNASYN	ampicillin sodium; sulbactam sodium	INJECTABLE;INJECTION	050608-005	Dec 10, 1993	AP	RX	Yes	Yes

UNASYN (Ampicillin/Sulbactam) Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

UNASYN, a combination antibiotic comprising ampicillin and sulbactam, faces a dynamic market influenced by rising antibiotic resistance, evolving clinical guidelines, and the competitive landscape of beta-lactamase inhibitor combinations. Developed initially by Pfizer, UNASYN's market presence is characterized by its established efficacy in treating specific bacterial infections, primarily those caused by susceptible Gram-positive and Gram-negative bacteria, including beta-lactamase producing strains.

What is the Current Market Position of UNASYN?

UNASYN's current market position is that of a well-established, albeit mature, broad-spectrum antibiotic. Its primary indications include upper and lower respiratory tract infections, urinary tract infections, intra-abdominal infections, and skin and soft tissue infections. The drug is available in both intravenous (IV) and intramuscular (IM) formulations, facilitating various clinical settings.

Globally, the antibiotic market is experiencing significant shifts. The increasing prevalence of multidrug-resistant organisms (MDROs) necessitates careful stewardship of existing antibiotics while driving research into novel agents. UNASYN, while effective against many common pathogens, faces competition from newer generation cephalosporins, carbapenems, and other beta-lactamase inhibitor combinations that offer broader spectrum activity or improved resistance profiles.

However, UNASYN maintains a significant role in certain regions and for specific indications where its cost-effectiveness and established pharmacokinetic profile are advantageous. Its continued use is supported by its inclusion in various treatment guidelines for susceptible infections. The market for UNASYN is also influenced by the genericization of the drug, leading to increased price competition and a focus on market access and supply chain reliability.

What are the Key Drivers and Restraints for UNASYN?

Key Drivers:

• Established Efficacy Against Specific Pathogens: UNASYN remains a reliable option for infections caused by susceptible strains of Staphylococcus aureus, Escherichia coli, Klebsiella species, Proteus species, and Haemophilus influenzae [1]. Its sulbactam component inhibits beta-lactamase enzymes, extending the spectrum of ampicillin activity against resistant strains.
• Cost-Effectiveness: In many markets, UNASYN, particularly its generic formulations, offers a cost-effective treatment option compared to newer, more expensive broad-spectrum antibiotics. This is a significant driver in resource-limited settings and for institutions prioritizing budget adherence.
• Inclusion in Clinical Guidelines: UNASYN is listed in numerous national and international treatment guidelines for specific infectious diseases, such as uncomplicated urinary tract infections and certain types of intra-abdominal infections. These guidelines influence prescribing patterns.
• Established Manufacturing and Supply Chains: As a long-standing antibiotic, UNASYN benefits from robust manufacturing processes and well-established global supply chains, ensuring consistent availability.
• Use in Combination Therapy: UNASYN can be used in combination with other agents to broaden coverage or manage polymicrobial infections, enhancing its clinical utility.

Key Restraints:

• Rising Antibiotic Resistance: The increasing global prevalence of extended-spectrum beta-lactamase (ESBL)-producing bacteria and carbapenem-resistant Enterobacteriaceae (CRE) poses a significant threat to the efficacy of UNASYN. Susceptibility testing is crucial for its appropriate use.
• Emergence of Broader-Spectrum Alternatives: Newer antibiotics, including advanced cephalosporins (e.g., ceftazidime-avibactam), carbapenems, and other beta-lactamase inhibitor combinations (e.g., piperacillin-tazobactam), offer broader coverage against more resistant pathogens and are increasingly favored for empirical treatment of severe infections.
• Stricter Antibiotic Stewardship Programs: Growing emphasis on antibiotic stewardship programs encourages the judicious use of antibiotics, often favoring narrower-spectrum agents or reserving broad-spectrum options for documented or highly suspected resistant infections. This can limit the empirical use of UNASYN.
• Adverse Event Profile: Like other penicillins, UNASYN can cause hypersensitivity reactions, gastrointestinal disturbances, and other side effects, which may limit its use in certain patient populations.
• Limited Activity Against Certain Pathogens: UNASYN is not effective against Pseudomonas aeruginosa strains that produce certain beta-lactamases, nor is it effective against MRSA or Enterococcus faecium [2].

What is the Competitive Landscape for UNASYN?

The competitive landscape for UNASYN is multifaceted, encompassing other beta-lactam/beta-lactamase inhibitor combinations, as well as antibiotics from different drug classes.

Direct Competitors (Beta-Lactam/Beta-Lactamase Inhibitor Combinations):

• Piperacillin-Tazobactam (e.g., Zosyn): This combination offers a broader spectrum of activity than UNASYN, including better coverage against Pseudomonas aeruginosa. It is often the preferred choice for severe infections, hospital-acquired pneumonia, and intra-abdominal infections where broader empirical coverage is necessary [3].
• Amoxicillin-Clavulanate (e.g., Augmentin): While amoxicillin-clavulanate has oral formulations that UNASYN lacks, its IV counterpart competes in similar indications. However, piperacillin-tazobactam generally possesses a wider spectrum.
• Ceftolozane-Tazobactam (e.g., Zerbaxa): This newer combination is specifically designed for resistant Gram-negative infections, including complicated intra-abdominal infections and hospital-acquired/ventilator-associated pneumonia, offering improved activity against difficult-to-treat pathogens like resistant Pseudomonas aeruginosa [4].
• Ceftazidime-Avibactam (e.g., Avycaz): Another advanced combination targeting resistant Gram-negative bacteria, including ESBL producers and some carbapenem-resistant strains. It is a key competitor for infections where resistance is a significant concern [5].

Indirect Competitors (Other Antibiotic Classes):

• Carbapenems (e.g., Imipenem, Meropenem, Ertapenem): These are considered broad-spectrum agents with excellent activity against many Gram-positive and Gram-negative bacteria, including many ESBL producers. They are often reserved for severe or complicated infections due to resistance concerns and potential for Clostridioides difficile infection. Ertapenem has a narrower spectrum, not covering Pseudomonas, Acinetobacter, or Enterococcus.
• Fluoroquinolones (e.g., Levofloxacin, Ciprofloxacin): These are effective against a range of Gram-positive and Gram-negative bacteria and are used for various infections, including UTIs and respiratory tract infections. However, resistance is a growing issue, and concerns regarding tendinopathy and other side effects exist.
• Aminoglycosides (e.g., Gentamicin, Tobramycin): Often used in combination with beta-lactams for serious Gram-negative infections, particularly when Pseudomonas is suspected.
• Vancomycin: The cornerstone for treating MRSA infections, but also used for severe Gram-positive infections.

The competitive intensity is highest in hospital settings where empirical treatment decisions are critical. The cost-effectiveness of generic UNASYN provides a competitive advantage in markets where budget constraints are paramount.

What is the Financial Trajectory and Market Size of UNASYN?

Quantifying the precise global market size and financial trajectory of UNASYN as a standalone product is challenging due to its long history of genericization and its inclusion in various branded and generic product portfolios. However, its market value is tied to the broader market for beta-lactamase inhibitor combinations and injectable antibiotics.

Estimated Market Size and Growth:

• The global antibiotic market is valued in the tens of billions of U.S. dollars annually. The beta-lactam and cephalosporin segments, which include UNASYN's class, represent a substantial portion of this market.
• Growth in this segment is often moderate, driven by increased infection rates in certain demographics and regions, but is increasingly tempered by the development of resistance and the shift towards novel therapies.
• For established generic antibiotics like UNASYN, market dynamics are more influenced by volume and geographic penetration than by significant price appreciation. The market is largely driven by demand in emerging economies and by its continued use in specific indications in developed markets.

Financial Performance Factors:

• Generic Competition: The primary driver of UNASYN's financial trajectory is intense competition from multiple generic manufacturers. This has led to significant price erosion from its original branded price.
• Volume-Based Sales: Revenue generation relies heavily on high sales volumes. Market access, formulary inclusion in hospitals, and physician prescribing habits are critical for maintaining volume.
• Geographic Distribution: Significant sales are likely in regions with higher infectious disease burdens and where UNASYN's cost-effectiveness is a key differentiator. Asia-Pacific and Latin America are likely key markets.
• Supply Chain Costs: Manufacturing efficiency and global logistics play a crucial role in maintaining profitability for generic products.
• Regulatory Landscape: Changes in regulatory requirements for antibiotic manufacturing and marketing can impact production costs and market access.
• Emerging Markets Penetration: Growth potential for UNASYN may be higher in emerging markets where access to newer, more expensive antibiotics is limited.

Projected Trajectory:

The financial trajectory for UNASYN is expected to be characterized by stable to declining revenue in mature markets due to competition from newer agents and antimicrobial stewardship. However, it may see continued volume-based growth in specific emerging markets where it remains a vital and accessible treatment option. Overall, the drug is likely to remain a significant contributor to revenue for generic manufacturers but is not anticipated to experience substantial market expansion in value terms.

What are the Regulatory and Policy Implications for UNASYN?

Regulatory and policy frameworks significantly impact the market for antibiotics like UNASYN, influencing their availability, pricing, and prescribing practices.

Key Regulatory and Policy Areas:

• Antimicrobial Resistance (AMR) Initiatives: Global and national strategies to combat AMR, such as those promoted by the WHO, encourage the judicious use of antibiotics. This can lead to stricter prescribing guidelines for older, broad-spectrum agents like UNASYN, favoring narrower-spectrum options or susceptibility-guided therapy. Policies promoting antimicrobial stewardship programs in healthcare institutions are a direct consequence.
• Drug Approval and Re-evaluation: While UNASYN is a long-established drug, regulatory agencies periodically review antibiotic safety and efficacy. Changes in prescribing information or label updates reflecting emerging resistance patterns or safety concerns could influence its use.
• Generic Drug Regulations: The regulatory pathways for generic drug approval are crucial. Manufacturers must demonstrate bioequivalence to the reference listed drug. Policies related to ANDA (Abbreviated New Drug Application) approvals and patent challenges influence the speed and number of generic entrants into the market, directly impacting UNASYN's pricing and competitive intensity.
• Pricing and Reimbursement Policies: Government policies on drug pricing, reimbursement by national health systems, and tender processes in public procurement significantly affect the commercial viability of generic antibiotics. UNASYN's cost-effectiveness positions it favorably in price-sensitive markets and procurement tenders.
• Manufacturing Standards (GMP): Adherence to Good Manufacturing Practices (GMP) is mandatory for all pharmaceutical manufacturers. Regulatory bodies like the FDA and EMA conduct inspections to ensure compliance, which can impact production continuity and market access for manufacturers.
• Incentives for New Antibiotic Development: While not directly affecting UNASYN's current market, policies aimed at incentivizing the development of novel antibiotics (e.g., market exclusivity extensions, tax credits) indirectly shape the future antibiotic landscape, potentially leading to a greater number of advanced alternatives that could further challenge UNASYN's market share.
• Import/Export Regulations: International trade agreements and country-specific import/export regulations for pharmaceuticals can influence the global distribution and availability of UNASYN.

The policy environment is increasingly geared towards preserving the efficacy of existing antibiotics and fostering innovation. This presents a dual challenge for UNASYN: maintaining its place in therapy through cost and proven utility while navigating an environment that prioritizes responsible antibiotic use and the development of novel solutions for resistant infections.

What are the Future Outlook and Strategic Considerations for UNASYN?

The future outlook for UNASYN is that of a mature, largely genericized antibiotic whose market relevance will be primarily defined by its cost-effectiveness and continued utility in specific clinical niches. Strategic considerations for stakeholders will focus on optimizing its existing market presence rather than pursuing significant growth.

Future Outlook:

• Continued Niche Utilization: UNASYN will likely persist as a treatment option for infections caused by susceptible organisms, particularly in settings where cost is a primary concern or where resistance to newer agents is not yet prevalent for specific pathogens.
• Geographic Divergence: Its importance may decline in highly developed healthcare systems with widespread access to newer broad-spectrum antibiotics and robust stewardship programs. Conversely, it may maintain or grow its presence in emerging markets with limited access to alternative therapies.
• Focus on Generic Manufacturers: The future market will be dominated by generic manufacturers who can produce and distribute the drug efficiently and at competitive prices. Brand loyalty or unique value propositions for the original branded product are minimal.
• Sustained Importance in Specific Guidelines: As long as UNASYN remains recommended in key clinical guidelines for specific infectious diseases, it will retain a baseline level of demand.

Strategic Considerations:

• Cost Optimization in Manufacturing and Supply Chain: For generic manufacturers, maintaining lean manufacturing processes, efficient global logistics, and robust supply chain management is paramount to competing on price and ensuring consistent availability.
• Market Access in Emerging Economies: Focusing on securing market access, favorable pricing, and distribution networks in emerging markets with a growing demand for essential antibiotics represents a key growth avenue.
• Evidence Generation for Stewardship: While challenging for a mature drug, generating or supporting research that demonstrates UNASYN's appropriate use in specific stewardship-aligned scenarios could help preserve its role and counter arguments for complete de-escalation.
• Partnerships and Licensing: Manufacturers may explore strategic partnerships or licensing agreements to expand geographic reach or secure access to specific markets.
• Portfolio Management: For companies that manufacture UNASYN, it will be managed as part of a broader portfolio of antibiotics, balancing its revenue contribution against the investment required for its production and market support. It is unlikely to be a focus of significant new R&D investment.
• Monitoring Resistance Trends: Continuous monitoring of local and regional resistance patterns is critical. This informs appropriate prescribing and highlights regions where UNASYN's utility may be declining fastest.

The strategic imperative for UNASYN is to leverage its established profile and cost-effectiveness to maintain its position in a competitive and evolving antibiotic market, rather than to drive significant future expansion.

Key Takeaways

• UNASYN is a mature, genericized antibiotic with established efficacy against specific bacterial infections but faces significant competition from newer agents and rising antibiotic resistance.
• Its cost-effectiveness remains a primary driver, particularly in emerging markets, while its use is constrained by the increasing prevalence of MDROs and the broader spectrum of alternative antibiotics.
• The market trajectory is characterized by volume-driven sales, price competition among generic manufacturers, and a focus on geographic penetration rather than significant value growth.
• Regulatory policies around AMR, generic drug approvals, and pricing significantly shape UNASYN's market access and commercial viability.
• Future strategies for UNASYN will center on cost optimization, emerging market access, and leveraging its role in specific clinical guidelines and stewardship programs, rather than on extensive R&D investment.

Frequently Asked Questions

• What are the most common bacterial infections treated by UNASYN? UNASYN is primarily used to treat upper and lower respiratory tract infections, urinary tract infections, intra-abdominal infections, and skin and soft tissue infections caused by susceptible bacteria.

• How does UNASYN combat antibiotic resistance? UNASYN contains sulbactam, a beta-lactamase inhibitor that protects ampicillin from degradation by bacterial beta-lactamase enzymes, thereby extending ampicillin's spectrum of activity against many resistant strains.

• What are the main differences between UNASYN and piperacillin-tazobactam? Piperacillin-tazobactam generally offers a broader spectrum of activity than UNASYN, including improved coverage against Pseudomonas aeruginosa, and is often preferred for more severe or hospital-acquired infections.

• Is UNASYN still considered a first-line treatment for any infections? While its empirical use has decreased in many developed nations due to stewardship and resistance, UNASYN may still be a first-line or recommended option for specific infections in certain clinical guidelines, particularly where susceptibility is confirmed and cost is a consideration.

• What is the impact of genericization on UNASYN's market price? Genericization has led to a significant reduction in UNASYN's market price compared to its original branded cost, making it a more accessible treatment option but also intensifying price-based competition among manufacturers.

Citations

[1] Lexicomp. (n.d.). Ampicillin/Sulbactam. Retrieved from Lexicomp Online. (Specific access date and URL would be required for a live citation, but this represents the type of source.)

[2] UpToDate. (n.d.). Ampicillin-sulbactam: Drug information. Retrieved from UpToDate. (Specific access date and URL would be required for a live citation, but this represents the type of source.)

[3] Pfizer Inc. (2021). ZOSYN® (piperacillin for injection, sulbactam for injection) [Prescribing Information]. Retrieved from FDA.gov.

[4] Merck & Co., Inc. (2023). ZERBAXA® (ceftolozane and tazobactam) for injection [Prescribing Information]. Retrieved from FDA.gov.

[5] AstraZeneca. (2023). AVYC AZ® (ceftazidime and avibactam) for injection [Prescribing Information]. Retrieved from FDA.gov.